Position of the Transparency Council – Beovu (brolucizumab)
At its meeting on 16 January 2023, the Transparency Council adopted Opinion No. 9/2023 on the evaluation of the medicine Beovu (brolucizumab) under the drug programme “Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0) under Part B: treatment of patients with diabetic macular oedema (DME)”,